Fda Drug Approval Calendar 2025

Fda Drug Approval Calendar 2025. 2020 FDA drug approvals AstraZeneca: EU Approves Imfinzi As First And Only Immunotherapy For LS - Small Cell Lung Cancer March 17, 2025 03:43 ET British drug major AstraZeneca Plc (AZN, AZN.L) announced Monday that its Imfinzi (durvalumab) has been approved in the European Union as first and only immunotherapy for limited-stage small cell lung cancer or LS-SCLC. If approved, neffy 1 mg is expected to be available by the end of May 2025

US FDA medical device approval chart Emergo
US FDA medical device approval chart Emergo from www.slideshare.net

Romvimza: vimseltinib: 2/14/2025: To treat symptomatic tenosynovial giant cell tumor for which surgical. Our enhanced FDA calendar integrates PDUFA dates, clinical trial primary completion dates, and working capital runway estimates into a single timeline that covers companies publicly traded in the U.S

US FDA medical device approval chart Emergo

APPROVED: 2.21.2025: Ctexli (chenodiol) Cerebrotendinous xanthomatosis: Mirum Therapeutics: APPROVED: 2.28.2025 Mirdametinib: Neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN) Springworks Therapeutics: APPROVED: 3.6.2025: Encelto (revakinagene taroretcel-lwey) Macular telangiectasia type 2 (MacTel) Neurotech. If approved, neffy 1 mg is expected to be available by the end of May 2025 Streamline your research and quickly compare the relative timing of competing catalysts.

Fda Approval List 2025 Olva Eleonora. AstraZeneca: EU Approves Imfinzi As First And Only Immunotherapy For LS - Small Cell Lung Cancer March 17, 2025 03:43 ET British drug major AstraZeneca Plc (AZN, AZN.L) announced Monday that its Imfinzi (durvalumab) has been approved in the European Union as first and only immunotherapy for limited-stage small cell lung cancer or LS-SCLC. FDA Calendar With our Free FDA Calendar, track upcoming PDUFA dates, FDA approvals, biotech catalysts, clinical trials, and regulatory events

Xipere Fda Approval. Grafapex (treosulfan) Lyophilized Powder for Injection The original 2 mg dose of neffy received FDA approval in August 2024 for patients weighing 30 kg or more.